Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

被引:283
|
作者
Lu, Yuanjun [1 ]
Chan, Yau-Tuen [1 ]
Tan, Hor-Yue [1 ]
Li, Sha [1 ]
Wang, Ning [1 ]
Feng, Yibin [1 ]
机构
[1] Univ Hong Kong, Sch Chinese Med, Pofulam, 10 Sassoon Rd, Hong Kong 000000, Peoples R China
关键词
Epigenetic modification; Cancer; Epi-drugs; Combination strategy; Tumour microenvironment; HISTONE DEACETYLASE INHIBITOR; RANDOMIZED PHASE-II; DNA METHYLTRANSFERASE INHIBITOR; MESSENGER-RNA METHYLATION; ACUTE MYELOID-LEUKEMIA; LONG NONCODING RNAS; IN-VITRO; HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; MESENCHYMAL TRANSITION;
D O I
10.1186/s12943-020-01197-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Epigenetic Cancer Therapy
    Das, Nabanita
    Kundu, Tapas K.
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (03) : 447 - 450
  • [42] Epigenetic regulation of the potential tumor suppressor gene, hLHX6.1, in human cervical cancer
    Jung, Samil
    Jeong, Dongjun
    Kim, Jinsun
    Yi, Lisha
    Koo, Keunhoe
    Lee, Jaehyouk
    Kim, Chang-Jin
    Kim, Chang-Hwan
    An, Sungwhan
    Yang, Young
    Lim, Jong-Seok
    Kim, Keun Il
    Lee, Myeong-Sok
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (03) : 859 - 869
  • [43] Epigenetic regulation in cancer therapy: From mechanisms to clinical advances
    Tao, Lei
    Zhou, Yue
    Luo, Yuan
    Qiu, Jiahao
    Xiao, Yuzhou
    Zou, Jiao
    Zhang, Yu
    Liu, Xingchen
    Yang, Xinyu
    Gou, Kun
    Xu, Jing
    Guan, Xinqi
    Cen, Xiaobo
    Zhao, Yinglan
    MEDCOMM-ONCOLOGY, 2024, 3 (01):
  • [44] y Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
    Elmallah, Mohammed I. Y.
    Micheau, Olivier
    CANCERS, 2019, 11 (06):
  • [45] Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy
    Zheng, Yujun George
    Wu, Jiang
    Chen, Ziyue
    Goodman, Masha
    MEDICINAL RESEARCH REVIEWS, 2008, 28 (05) : 645 - 687
  • [46] Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
    Heng, H. H.
    Liu, G.
    Stevens, J. B.
    Bremer, S. W.
    Ye, K. J.
    Ye, C. J.
    CURRENT DRUG TARGETS, 2010, 11 (10) : 1304 - 1316
  • [47] Epigenetic Regulation of Epithelial to Mesenchymal Transition in the Cancer Metastatic Cascade: Implications for Cancer Therapy
    Liu, Qiu-Luo
    Luo, Maochao
    Huang, Canhua
    Chen, Hai-Ning
    Zhou, Zong-Guang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] Autotaxin in Breast Cancer: Role, Epigenetic Regulation and Clinical Implications
    Drosouni, Andrianna
    Panagopoulou, Maria
    Aidinis, Vassilis
    Chatzaki, Ekaterini
    CANCERS, 2022, 14 (21)
  • [49] Genetic silencing of sGC β1 in cancer: role of epigenetic regulation
    Alex Sotolongo
    Ka Bian
    Ferid Murad
    BMC Pharmacology and Toxicology, 14 (Suppl 1)
  • [50] Epigenetic Profiling and Epigenetic Therapy in Cancer
    Issa, Jean-Pierre
    TUMOR BIOLOGY, 2008, 29 : 2 - 2